Significant efficacy of acotinib/acalabrutinib in the treatment of lymphoma

Acalabrutinib/Acalabrutinib, as a highly selective and potent Bruton tyrosine kinase (BTK) inhibitor, effectively inhibits the activity of BTK by binding to specific sites, and has shown significant efficacy in the treatment of mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Two important recent studies have further confirmed the excellent performance of acotinib in the treatment of these diseases.

In a study of 535 patients with previously untreated chronic lymphocytic leukemia (CLL), researchers compared acotinib alone and in combination with obinutuzumab, as well as a combination of obinutuzumab and another anticancer drug, chlorambucil. After approximately 28 months of treatment, only 8% of patients who received acomitinib plus otuzumab had died or had cancer progression, compared with 15% of patients who received acomitinib alone. By comparison, up to 53% of patients in the control group died or had their cancer worsen.

Another important study involving 310 patients focused on patients whose CLL relapsed or failed to respond to previous treatments. The study compared acotinib alone with other anticancer drugs, such as rituximab plus idelalisib or bendamustine. After about 16 months of treatment, only 17% of patients who received acotinib alone had died or had their cancer progress, compared with 44% of patients who received rituximab in combination. This significant difference further highlights the superiority of acotinib as monotherapy in the treatment of lymphoma.